Diabetic Kidney Disease: A Report From an ADA Consensus Conference

The incidence and prevalence of diabetes mellitus have grown significantly throughout the world, due primarily to the increase in type 2 diabetes. This overall increase in the number of people with diabetes has had a major impact on development of diabetic kidney disease (DKD), one of the most frequent complications of both types of diabetes. DKD is the leading cause of end-stage renal disease (ESRD), accounting for approximately 50% of cases in the developed world. Although incidence rates for ESRD attributable to DKD have recently stabilized, these rates continue to rise in high-risk groups such as middle-aged African Americans, Native Americans, and Hispanics. The costs of care for people with DKD are…

• A
  Amgen
• BS
  Bristol-Myers Squibb
• EL
  Eli Lilly and Company
• A
  AstraZeneca
• S
  Sanofi
• GS
  Gilead Sciences
• H
  Halozyme
• LP
  Luitpold Pharmaceuticals
• A
  Angion
• NN
  Novo Nordisk
• CL
  CSL Limited
• NI
  National Institutes of Health
• R
  Relypsa
• NI
  National Institute of Diabetes and Digestive and Kidney Diseases
• DS
  Daiichi Sankyo Europe